Drugs / WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01513109 | Dec 2011 → Dec 2013 | acute myeloid leukemia | Jules Bordet Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic | “A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T...” NCT01513109 ↗ |
| Known as | ASCI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01513109 ↗ |